A phase II study of FT-002 in U.S.
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs FT 002 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; Therapeutic Use
- 28 Jan 2025 New trial record
Latest Information Update: 28 Jan 2025